14450
document
Buprenorphine alone and in combination with naloxone in non-dependent humans . This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine , a mixed agonist-antagonist marketed as an analgesic and under development as a treatment for drug abuse . In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine ( 0.4 mg or 0.8 mg/70 kg ) alone and in combination with naloxone ( 0.4 mg or 0.8 mg/70 kg ) versus placebo . Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures . Concurrent naloxone attenuated the opioid agonist effects of buprenorphine . Thus , a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone .
14451
Intervention_Pharmacological
naloxone
14452
Intervention_Pharmacological
buprenorphine
14453
Intervention_Control
placebo
14454
Outcome_Physical
physiological and subjective measures
14455
Outcome_Physical
the opioid agonist effects
14456
Outcome_Other
abuse liability
14457
Participant_Sample-size
seven
14458
Participant_Condition
opioid abuser